Schechter Investment Advisors LLC Reduces Stock Position in Grifols, S.A. (NASDAQ:GRFS)

Schechter Investment Advisors LLC decreased its holdings in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 25.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 90,044 shares of the biotechnology company's stock after selling 30,358 shares during the period. Schechter Investment Advisors LLC's holdings in Grifols were worth $670,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Whitebox Advisors LLC boosted its stake in shares of Grifols by 56.2% during the third quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company's stock worth $37,487,000 after buying an additional 1,519,093 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Grifols by 144.0% during the third quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company's stock worth $17,782,000 after buying an additional 1,181,959 shares during the period. Anthracite Investment Company Inc. acquired a new stake in Grifols in the third quarter valued at about $5,457,000. Barclays PLC lifted its position in Grifols by 381.2% in the third quarter. Barclays PLC now owns 592,552 shares of the biotechnology company's stock valued at $5,261,000 after purchasing an additional 469,401 shares during the period. Finally, Verition Fund Management LLC acquired a new stake in Grifols in the third quarter valued at about $2,636,000.

Grifols Stock Performance

NASDAQ:GRFS traded down $0.07 during mid-day trading on Friday, reaching $8.43. The stock had a trading volume of 1,216,779 shares, compared to its average volume of 1,307,326. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The firm has a market capitalization of $5.80 billion, a price-to-earnings ratio of 7.21 and a beta of 0.40. Grifols, S.A. has a twelve month low of $5.68 and a twelve month high of $9.96. The business has a 50 day simple moving average of $7.46 and a 200 day simple moving average of $8.14.

Remove Ads

Analyst Ratings Changes

Separately, Morgan Stanley assumed coverage on shares of Grifols in a research report on Wednesday, February 12th. They issued an "overweight" rating for the company.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.